The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - BioNTech (I); GANYMED Pharmaceuticals
Leadership - BioNTech (I); GANYMED Pharmaceuticals
Stock and Other Ownership Interests - BioNTech (I); GANYMED Pharmaceuticals
Consulting or Advisory Role - GANYMED Pharmaceuticals (I)
Patents, Royalties, Other Intellectual Property - BioNTech; BioNTech (I); GANYMED Pharmaceuticals; GANYMED Pharmaceuticals (I)
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.
 
Salah-Eddin Al-Batran
Consulting or Advisory Role - Celgene; Lilly; Merck; Roche
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma
 
Martin H. Schuler
Honoraria - Alexion Pharmaceuticals; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Lilly; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Inanovate; Lilly; Novartis
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - University Duisburg-Essen
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Inanovate; Lilly; Pfizer
 
Zanete Zvirbule
No Relationships to Disclose
 
Georgiy Manikhas
No Relationships to Disclose
 
Florian Lordick
Honoraria - Amgen; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Nordic Group; Roche Pharma AG
Consulting or Advisory Role - BioNTech; GANYMED Pharmaceuticals; Roche (Inst)
Research Funding - Boehringer Ingelheim (Inst); Fresenius Biotech; GlaxoSmithKline (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Bayer; Roche; Taiho Pharmaceutical
 
Andriy Rusyn
No Relationships to Disclose
 
Yuriy Vynnyk
No Relationships to Disclose
 
Ihor Vynnychenko
No Relationships to Disclose
 
Natalia Fadeeva
Research Funding - Chelyabinsk Regional Clinical Oncology Dispensary
 
Marina Nechaeva
No Relationships to Disclose
 
Assen Dudov
No Relationships to Disclose
 
Evgeny Gotovkin
No Relationships to Disclose
 
Alexander Pecheniy
No Relationships to Disclose
 
Igor Bazin
Speakers' Bureau - Bayer
 
Igor Bondarenko
No Relationships to Disclose
 
Bohuslav Melichar
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Novartis; Roche
 
Christian Mueller
Employment - GANYMED Pharmaceuticals
 
Christoph Huber
Stock and Other Ownership Interests - BioNTech; GANYMED Pharmaceuticals
Consulting or Advisory Role - BioNTech; GANYMED Pharmaceuticals
Other Relationship - BioNTech; GANYMED Pharmaceuticals
 
Oezlem Tureci
No Relationships to Disclose
 
Ugur Sahin
Employment - BioNTech; GANYMED Pharmaceuticals (I)
Leadership - BioNTech; GANYMED Pharmaceuticals (I)
Stock and Other Ownership Interests - BioNTech; GANYMED Pharmaceuticals (I)
Consulting or Advisory Role - GANYMED Pharmaceuticals
Patents, Royalties, Other Intellectual Property - BioNTech; BioNTech (I); GANYMED Pharmaceuticals; GANYMED Pharmaceuticals (I)